Table 2.
Demographic and clinical variables.
| Patients who completed CRT (n = 20) | |
|---|---|
| M (SD) | |
| Years of education | 11.65 (2.08) |
| Baseline antipsychotics total dose (mg/day in clz equivalents) | 615.38 (539.89) |
| Follow-up antipsychotics total dose (mg/day in clz equivalents) | 587.07 (414.45) |
| SAPS total, baselinea | 25.26 (14.06)b |
| SAPS total, follow-upa | 19.05 (13.05)b |
| SANS total, baselinea | 26.42 (13.62) |
| SANS total, follow-upa | 31.05 (12.95) |
| WASI FSIQ | 90.30 (11.89) |
| Global cognitive composite score (CSRB), baseline | −1.51 (1.10) |
| Global cognitive composite score (CSRB), follow-up | −1.36 (1.17) |
| BCIS total score, baseline | 2.70 (6.24) |
| BCIS total score, follow-up | 2.75 (4.98) |
| Diagnosis | n (%) |
| Schizophrenia | 1 (5) |
| Schizophrenia, paranoid | 8 (40) |
| Schizoaffective disorder | 6 (30) |
| Schizophrenia, undifferentiated | 4 (20) |
| Psychosis NOS | 1 (5) |
a n = 19; SAPS and SANS were not used for one patient.
bThe difference in SAPS total score between baseline and follow-up is statistically significant (t (18) = 2.41; p = 0.03).